Figure 6 | Leukemia

Figure 6

From: Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia

Figure 6

Jak2 inhibition by WP1193 inhibited solid tumor formation caused by IM-resistant K562 cells and strongly reduced tumors effects caused by Bcr–Abl T315I. (a) WP1193 inhibits solid tumor formation in nude mice injected subcutaneously (s.c) with 5 million K562-R cells. Five mice were injected with WP1193 (30 mg/kg) every 48 h beginning 12 days after injection of cells through 22 days. (b) Quantitation of tumor weight from five mice. (c and d) WP1193 reduced the weight of liver and spleens (right spleen in figure) in leukemic injected with Bcr–Abl T315I+ BaF3 cells (2.5 million cells). Mice were injected every 48 h by the i.p. route with WP1193 beginning 1 day after cell inoculation and killed 1 day after the seventh injection. (e) Reduction of spleen weight by WP1193 in mice injected with Bcr–Abl T315I BaF3 cells. (f) Model describing how Jak2 regulates signaling in CML cells.

Back to article page